by Fred Pennic
December 18, 2020

We recently spoke with Skyler Stein, President of Dutch biotechnology company Gladskin to learn more about its global endolysin technology that uses its science to improve inflammatory skin conditions by rebalancing the skin microbiome. Gladskin’s parent company, Micreos, raised about $36.7M in funding last year for its endolysin technology that is poised to replace many antibiotics and overcome some of the challenges of antimicrobial resistance.

HITC: Skyler, can you speak more about endolysin technology? Can you share the results of clinical trials related to AD (Atopid Dermatitis) with us?

Stein: Endolysin technology is cutting edge science, but actually it is based on three billion years of nature’s evolution to keep our skin healthy. Our endolysin is so targeted – it only targets a single bacterial species that is causing the problem, and it keeps the rest of your skin’s microbiome healthy. Based on the data from studies we’ve performed, resistance is not expected, making it a safe option to use daily. It doesn’t have the treatment limitations, side effects, or withdrawal symptoms that you can have with immunosuppressants, antibiotics, and steroids.

Micreos launched its double-blinded placebo-controlled Phase I/2A trial for the treatment of mild to moderate Atopic Dermatitis in September 2020.

To read the rest of the conversation, please visit the original article here.

Share this: